Treatment of vestibular schwannoma cells with ErbB inhibitors

Matthew L. Bush, Sarah S. Burns, Janet Oblinger, Sholpan Davletova, Long Sheng Chang, D. Bradley Welling, Abraham Jacob

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

HYPOTHESIS: Aberrant phosphorylation of ErbB family receptor tyrosine kinases (RTK) in human vestibular schwannomas (VSs) renders them susceptible to growth suppression by RTK inhibitors. BACKGROUND: Recent evidence has implicated increased ErbB family receptor tyrosine kinase signaling in VS tumorigenesis; however, the characterization of ErbB receptor activity and the chemotherapeutic potential of RTK inhibitors in VS treatment have not been fully explored. METHODS: To confirm phosphorylation of ErbB receptors in VS, protein extracts from paired VS tumor-vestibular nerve samples were examined using phospho-RTK arrays. ErbB receptor phosphorylation was similarly examined in cultured schwannoma cells, normal Schwann cells, and VS tumor tissues using Western blotting. Also, VS tumor sections were immunostained for members of the ErbB receptor family. The effects of RTK inhibitors on ErbB phosphorylation and cell proliferation were assessed in schwannoma cells after epidermal growth factor receptor (EGFR) inhibitor (Erlotinib) and EGFR/ErbB2 inhibitor (Lapatinib) treatment. RESULTS: VS tumor tissues consistently demonstrated higher levels of phosphorylated ErbB3 compared with paired vestibular nerves. However, cultured VS, malignant schwannoma, and normal Schwann cells demonstrated EGFR phosphorylation. Immunohistochemistry confirmed high expression of ErbB3 in a series of VS tumor sections. Erlotinib inhibited schwannoma cell proliferation with an IC50 value of 2.5 μmol/L, whereas Lapatinib was less potent for growth inhibition. Erlotinib treatment resulted in a decrease of multiple phospho-ErbB receptors in schwannoma cells. CONCLUSION: VS variably express activated ErbB receptors with consistently higher levels of phospho-ErbB3 expression relative to paired vestibular nerve samples. Chemotherapeutic targeting of ErbB3 may be a novel means of inhibiting VS growth.

Original languageEnglish (US)
Pages (from-to)244-257
Number of pages14
JournalOtology and Neurotology
Volume33
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Acoustic Neuroma
Neurilemmoma
Receptor Protein-Tyrosine Kinases
Vestibular Nerve
Phosphorylation
Therapeutics
Epidermal Growth Factor Receptor
Schwann Cells
Neoplasms
Protein-Tyrosine Kinases
Growth
Cell Proliferation
ErbB Receptors
Inhibitory Concentration 50
Cultured Cells
Carcinogenesis
Western Blotting
Immunohistochemistry

Keywords

  • EGFR
  • ErbB2
  • ErbB3
  • ErbB4
  • Erlotinib
  • Lapatinib
  • Vestibular schwannoma

ASJC Scopus subject areas

  • Otorhinolaryngology
  • Clinical Neurology
  • Sensory Systems
  • Medicine(all)

Cite this

Bush, M. L., Burns, S. S., Oblinger, J., Davletova, S., Chang, L. S., Welling, D. B., & Jacob, A. (2012). Treatment of vestibular schwannoma cells with ErbB inhibitors. Otology and Neurotology, 33(2), 244-257. https://doi.org/10.1097/MAO.0b013e31823e287f

Treatment of vestibular schwannoma cells with ErbB inhibitors. / Bush, Matthew L.; Burns, Sarah S.; Oblinger, Janet; Davletova, Sholpan; Chang, Long Sheng; Welling, D. Bradley; Jacob, Abraham.

In: Otology and Neurotology, Vol. 33, No. 2, 02.2012, p. 244-257.

Research output: Contribution to journalArticle

Bush, ML, Burns, SS, Oblinger, J, Davletova, S, Chang, LS, Welling, DB & Jacob, A 2012, 'Treatment of vestibular schwannoma cells with ErbB inhibitors', Otology and Neurotology, vol. 33, no. 2, pp. 244-257. https://doi.org/10.1097/MAO.0b013e31823e287f
Bush ML, Burns SS, Oblinger J, Davletova S, Chang LS, Welling DB et al. Treatment of vestibular schwannoma cells with ErbB inhibitors. Otology and Neurotology. 2012 Feb;33(2):244-257. https://doi.org/10.1097/MAO.0b013e31823e287f
Bush, Matthew L. ; Burns, Sarah S. ; Oblinger, Janet ; Davletova, Sholpan ; Chang, Long Sheng ; Welling, D. Bradley ; Jacob, Abraham. / Treatment of vestibular schwannoma cells with ErbB inhibitors. In: Otology and Neurotology. 2012 ; Vol. 33, No. 2. pp. 244-257.
@article{954ffc05c3304779ac073ab3c0b57e8e,
title = "Treatment of vestibular schwannoma cells with ErbB inhibitors",
abstract = "HYPOTHESIS: Aberrant phosphorylation of ErbB family receptor tyrosine kinases (RTK) in human vestibular schwannomas (VSs) renders them susceptible to growth suppression by RTK inhibitors. BACKGROUND: Recent evidence has implicated increased ErbB family receptor tyrosine kinase signaling in VS tumorigenesis; however, the characterization of ErbB receptor activity and the chemotherapeutic potential of RTK inhibitors in VS treatment have not been fully explored. METHODS: To confirm phosphorylation of ErbB receptors in VS, protein extracts from paired VS tumor-vestibular nerve samples were examined using phospho-RTK arrays. ErbB receptor phosphorylation was similarly examined in cultured schwannoma cells, normal Schwann cells, and VS tumor tissues using Western blotting. Also, VS tumor sections were immunostained for members of the ErbB receptor family. The effects of RTK inhibitors on ErbB phosphorylation and cell proliferation were assessed in schwannoma cells after epidermal growth factor receptor (EGFR) inhibitor (Erlotinib) and EGFR/ErbB2 inhibitor (Lapatinib) treatment. RESULTS: VS tumor tissues consistently demonstrated higher levels of phosphorylated ErbB3 compared with paired vestibular nerves. However, cultured VS, malignant schwannoma, and normal Schwann cells demonstrated EGFR phosphorylation. Immunohistochemistry confirmed high expression of ErbB3 in a series of VS tumor sections. Erlotinib inhibited schwannoma cell proliferation with an IC50 value of 2.5 μmol/L, whereas Lapatinib was less potent for growth inhibition. Erlotinib treatment resulted in a decrease of multiple phospho-ErbB receptors in schwannoma cells. CONCLUSION: VS variably express activated ErbB receptors with consistently higher levels of phospho-ErbB3 expression relative to paired vestibular nerve samples. Chemotherapeutic targeting of ErbB3 may be a novel means of inhibiting VS growth.",
keywords = "EGFR, ErbB2, ErbB3, ErbB4, Erlotinib, Lapatinib, Vestibular schwannoma",
author = "Bush, {Matthew L.} and Burns, {Sarah S.} and Janet Oblinger and Sholpan Davletova and Chang, {Long Sheng} and Welling, {D. Bradley} and Abraham Jacob",
year = "2012",
month = "2",
doi = "10.1097/MAO.0b013e31823e287f",
language = "English (US)",
volume = "33",
pages = "244--257",
journal = "Otology and Neurotology",
issn = "1531-7129",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Treatment of vestibular schwannoma cells with ErbB inhibitors

AU - Bush, Matthew L.

AU - Burns, Sarah S.

AU - Oblinger, Janet

AU - Davletova, Sholpan

AU - Chang, Long Sheng

AU - Welling, D. Bradley

AU - Jacob, Abraham

PY - 2012/2

Y1 - 2012/2

N2 - HYPOTHESIS: Aberrant phosphorylation of ErbB family receptor tyrosine kinases (RTK) in human vestibular schwannomas (VSs) renders them susceptible to growth suppression by RTK inhibitors. BACKGROUND: Recent evidence has implicated increased ErbB family receptor tyrosine kinase signaling in VS tumorigenesis; however, the characterization of ErbB receptor activity and the chemotherapeutic potential of RTK inhibitors in VS treatment have not been fully explored. METHODS: To confirm phosphorylation of ErbB receptors in VS, protein extracts from paired VS tumor-vestibular nerve samples were examined using phospho-RTK arrays. ErbB receptor phosphorylation was similarly examined in cultured schwannoma cells, normal Schwann cells, and VS tumor tissues using Western blotting. Also, VS tumor sections were immunostained for members of the ErbB receptor family. The effects of RTK inhibitors on ErbB phosphorylation and cell proliferation were assessed in schwannoma cells after epidermal growth factor receptor (EGFR) inhibitor (Erlotinib) and EGFR/ErbB2 inhibitor (Lapatinib) treatment. RESULTS: VS tumor tissues consistently demonstrated higher levels of phosphorylated ErbB3 compared with paired vestibular nerves. However, cultured VS, malignant schwannoma, and normal Schwann cells demonstrated EGFR phosphorylation. Immunohistochemistry confirmed high expression of ErbB3 in a series of VS tumor sections. Erlotinib inhibited schwannoma cell proliferation with an IC50 value of 2.5 μmol/L, whereas Lapatinib was less potent for growth inhibition. Erlotinib treatment resulted in a decrease of multiple phospho-ErbB receptors in schwannoma cells. CONCLUSION: VS variably express activated ErbB receptors with consistently higher levels of phospho-ErbB3 expression relative to paired vestibular nerve samples. Chemotherapeutic targeting of ErbB3 may be a novel means of inhibiting VS growth.

AB - HYPOTHESIS: Aberrant phosphorylation of ErbB family receptor tyrosine kinases (RTK) in human vestibular schwannomas (VSs) renders them susceptible to growth suppression by RTK inhibitors. BACKGROUND: Recent evidence has implicated increased ErbB family receptor tyrosine kinase signaling in VS tumorigenesis; however, the characterization of ErbB receptor activity and the chemotherapeutic potential of RTK inhibitors in VS treatment have not been fully explored. METHODS: To confirm phosphorylation of ErbB receptors in VS, protein extracts from paired VS tumor-vestibular nerve samples were examined using phospho-RTK arrays. ErbB receptor phosphorylation was similarly examined in cultured schwannoma cells, normal Schwann cells, and VS tumor tissues using Western blotting. Also, VS tumor sections were immunostained for members of the ErbB receptor family. The effects of RTK inhibitors on ErbB phosphorylation and cell proliferation were assessed in schwannoma cells after epidermal growth factor receptor (EGFR) inhibitor (Erlotinib) and EGFR/ErbB2 inhibitor (Lapatinib) treatment. RESULTS: VS tumor tissues consistently demonstrated higher levels of phosphorylated ErbB3 compared with paired vestibular nerves. However, cultured VS, malignant schwannoma, and normal Schwann cells demonstrated EGFR phosphorylation. Immunohistochemistry confirmed high expression of ErbB3 in a series of VS tumor sections. Erlotinib inhibited schwannoma cell proliferation with an IC50 value of 2.5 μmol/L, whereas Lapatinib was less potent for growth inhibition. Erlotinib treatment resulted in a decrease of multiple phospho-ErbB receptors in schwannoma cells. CONCLUSION: VS variably express activated ErbB receptors with consistently higher levels of phospho-ErbB3 expression relative to paired vestibular nerve samples. Chemotherapeutic targeting of ErbB3 may be a novel means of inhibiting VS growth.

KW - EGFR

KW - ErbB2

KW - ErbB3

KW - ErbB4

KW - Erlotinib

KW - Lapatinib

KW - Vestibular schwannoma

UR - http://www.scopus.com/inward/record.url?scp=84856008727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856008727&partnerID=8YFLogxK

U2 - 10.1097/MAO.0b013e31823e287f

DO - 10.1097/MAO.0b013e31823e287f

M3 - Article

VL - 33

SP - 244

EP - 257

JO - Otology and Neurotology

JF - Otology and Neurotology

SN - 1531-7129

IS - 2

ER -